27 September 2018

What Medicinal Chemists need to know about Biology II

Organised by:

SCI's Young Chemists' Panel

London, UK

Registration Closed

This event is no longer available for registration.

Synopsis
After the success of the opening installment last year, 2018 will see the return of 'What Medicinal Chemists Need to Know about Biology', the exciting and informative new series of conferences aimed at bridging the gap between medicinal chemistry and biology. This second event in this series, designed to aid chemists in understanding the features and challenges of the biological aspects of pharmaceutical research, will focus on the in vivo aspects of drug discovery biology, including topics such as:

 

  • Animal disease models
  • Phenotypic screening and target identification
  • PET tracers and biomarkers
Experienced speakers from leading pharmaceutical companies will deliver informative and interactive lectures, backed up by relevant case studies.
Attendees
The event is aimed at organic chemists (graduate or PhD) working within a pharmaceutical research environment and students thinking about a career in this sector. Participants are provided with a booklet containing the material presented. Attendees need not have attended part 1 in 2017.  
Programme
09.15 Registration and refreshments
09.55 Opening remarks
10.05 An introduction to in vivo pharmacology in drug discovery
Alex Vugler, UCB UK
10.55 What makes a good target? Identification and validation of targets for drug discovery
Peter Joyce, Grey Wolf Therapeutics
11.45 Refreshment break
12.10 Preclinical and clinical utilisation of biomarkers in oncology drug discovery
Chris Morrow, AstraZeneca
13.00 Lunch and exhibition
14.00 Synaptic Vesicle Protein 2A (SV2A): from phenotypic screen and target identification to drug approval and biomarker development
Joel Mercier, UCB Belgium
14.55 Following the pharmacological audit trail: from binding to efficacy with CHK1 inhibitors
Ian Collins, Institute of Cancer Research
15.50 Refreshment break
16.20 Application of in vivo PKPD to determine target engagement and mechanism of action for anti-inflammatory projects
Simon Peace, GlaxoSmithKline
17.15 Final Q&A and closing statements
17.30 Networking and refreshments

Venue and Contact

SCI

14/15 Belgrave Square
London
SW1X 8PS

Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org


Fees

Early bird fees before Tuesday 4 September 2018

£125 SCI Member
£40 SCI Student Member
£65 SCI Subsidised Member
£17 Non-Member

Standard fees after Tuesday 4 September 2018

£175 SCI Member
£55 SCI Student Member
£90 SCI Subsidised Member
£240 Non-Member

SCI Platinum Corporate Members receive 25% off the above rates.

Become an SCI Member and save on this and future events

See Membership Options

Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations


CPD Info

SCI Members attending this meeting are able to claim CPD points.

sci cpd


Sponsors

Organising Committee
  • Peter Blencowe, SCI / Cancer Technology
  • Ed Cochrane, SCI / Sygnature Discovery
  • Max Espensen, SCI / Pharmaron
  • Liz Jones, SCI / Syngenta
  • Michael Lainchbury, SCI / Charles River Laboratories
  • Gail Wrigley, SCI / AstraZeneca